For Life Sciences venture companies, health-related innovations ready for clinical trials are being accelerated, through a Memorandum of Understanding between McMaster Innovation Park (MIP) and the Integrated Management Platform to Accelerate Clinical Trials (IMPACT) at the University of Calgary (UCalgary).
The MOU facilitates access to the leading-edge IMPACT clinical trial program for MIP tenant life sciences ventures, while providing opportunities for growing UCalgary IMPACT ventures to advance toward commercialization and manufacturing at MIP.
John Wilson, CEO and President of Innovate Calgary, the innovation company of the University of Calgary, adds that “Innovate Calgary is always looking for ways to strengthen the innovation ecosystem in Alberta and Canada. This cross-provincial Agreement will enable Calgary-based small and mid-size health tech enterprises to access more resources and opportunities to manufacture their discoveries. We look forward to helping MIP ventures with their clinical trials in order to bring more Canadian bio-med discoveries to market and strengthen our national biotech and pharma industries”.
Read the full story Learn more about IMPACT